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Abstract
Purpose At present, the only approved fluorescent tracer for
clinical near-infrared fluorescence-guided sentinel node
(SN) detection is indocyanine green (ICG), but the use of
this tracer is limited due to its poor retention in the SN
resulting in the detection of higher tier nodes. We describe
the development and characterization of a next-generation
fluorescent tracer, nanocolloidal albumin-IRDye 800CW
that has optimal properties for clinical SN detection
Methods The fluorescent dye IRDye 800CW was covalent-
ly coupled to colloidal human serum albumin (HSA) par-
ticles present in the labelling kit Nanocoll in a manner
compliant with current Good Manufacturing Practice. Char-
acterization of nanocolloidal albumin-IRDye 800CW in-
cluded determination of conjugation efficiency, purity,
stability and particle size. Quantum yield was determined
in serum and compared to that of ICG. For in vivo evalua-
tion a lymphogenic metastatic tumour model in rabbits was
used. Fluorescence imaging was performed directly after
peritumoral injection of nanocolloidal albumin-IRDye
800CW or the reference ICG/HSA (i.e. ICG mixed with
HSA), and was repeated after 24 h, after which fluorescent
lymph nodes were excised.
Results Conjugation of IRDye 800CW to nanocolloidal albu-
min was always about 50% efficient and resulted in a stable
and pure product without affecting the particle size of the
nanocolloidal albumin. The quantum yield of nanocolloidal
albumin-IRDye 800CW was similar to that of ICG. In vivo
evaluation revealed noninvasive detection of the SN within
5 min of injection of either nanocolloidal albumin-IRDye
800CW or ICG/HSA. No decrease in the fluorescence signal
from SN was observed 24 h after injection of the nanocolloi-
dal albumin-IRDye 800CW, while a strong decrease or com-
plete disappearance of the fluorescence signal was seen 24 h
after injection of ICG/HSA. Fluorescence-guided SN biopsy
was very easy.
Conclusion Nanocolloidal albumin-IRDye 800CW is a
promising fluorescent tracer with optimal kinetic features
for SN detection.
Keywords Nanocolloidalalbumin.IRDye800CW.ICG.
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The sentinel node (SN) procedure is a diagnostic staging
procedure, which is applied in a variety of tumour types,
including head and neck squamous cell carcinoma
(HNSCC) [1, 2]. The identification and rough localization
of the SN is generally based on the results of preoperative
lymphoscintigraphy using planar or SPECT imaging, per-
formed after peritumoral injections of a
99mTc-labelled colloid
(in Europe generally
99mTc-Nanocoll).
To pinpoint the exact localization of the SN, so that the
duration and extent of surgical exploration is minimized, intra-
operative gamma probe-guided detection and blue dye lym-
phography are used. The gamma probe is used to guide the
surgeon to the SN, which still contains sufficient amounts of
radiocolloidatthetimeofsurgery.Thelimitationofthegamma
probe, however, is the lack of real-time visualization of the SN
and information about SN depth. Moreover, as a result of high
radioactivity arising from the injection site, detection of a SN
close to the tumour may be difficult. Blue dye is injected in the
same way as the radiocolloid, just before surgery, allowing
real-time lymphatic mapping. Blue dye follows lymphatic
vessels and accumulates in the draining lymph nodes staining
them blue [3]. However, real-time detection of this blue stain-
ing is only possible if there is no overlying tissue. Moreover,
bluedyeisarelatively lowmolecularweightcompound witha
very poor retention in the SN and is therefore present for a
short time. As a consequence, the use of blue dye is of limited
added value in the head and neck area [4].
The use ofnear-infrared (NIR) fluorescenceimagingmight
be an option for improving current clinical procedures. NIR
fluorescence allows high-resolution dynamic imaging of su-
perficial tissuelayerswithouta radiation burdentothe patient,
and can be used for real-time intraoperative visualization of
the location of the SN. In addition, in contrast to the blue dye-
guided method, NIR fluorescence detection might be possible
even if the SN is covered by tissue. Consequently, it might
make the intraoperative use of the gamma probe and blue dye
superfluous, especially when retention of the fluorescent trac-
er in the SN is good. At present, the only FDA-approved NIR
fluorescent compound that has been extensively evaluated for
SN detection is indocyanine green (ICG) [5–10]. ICG-guided
SN detection has been proven to be feasible in, for example,
breast cancer and skin cancer, with comparable or slightly
better detection rates than conventional techniques [8–13].
In these studies, relatively rapid passage of ICG through the
SN was observed, resulting in the detection of higher tier
nodeswhentheidentificationtimeincreasedfrom,forexample,
10 to 20 min [11].
IRDye 800CW is a promising next-generation NIR fluoro-
phore. This NIR fluorophore shows less nonspecific binding
and can, in contrast to ICG, be covalently conjugated to a
broad range of biomolecules [14, 15]. This property allows
conjugation of IRDye 800CW to colloidal human serum albu-
min (HSA) particles such those present in Nanocoll labelling
kits (here referred to as nanocolloidal albumin), which is
considered to be the most attractive carrier compound for SN
detection (“gold standard”), since this
99mTc-labelled colloid
has been widely used for many years in the clinical SN proce-
dures in Europe. The principles of IRDye 800CW conjugation
to nanocolloidal albumin were described by Ohnishi et al. in
2005 [16]aspart ofacomparative preclinical evaluation. Since
then, the SN concept has been established for solid tumours
other than breast tumours and melanoma. Furthermore, IRDye
800CW is produced in a manner compliant with current Good
Manufacturing Practice (cGMP). Clinical evaluation of IRDye
800CW is now possible, since toxicity studies did not reveal
pathological evidence of toxicity [17] and, together with the
filing of a Drug Master File at the US FDA, an Active Sub-
stance Master File has been filed with the Dutch regulatory
authorities in support of an Investigational Medical Product
Dossier for an IRDye 800CW-labelled targeted agent. Data
from these studies will enable the filing of investigational new
drug applications, e.g. nanocolloidal albumin-IRDye 800CW,
in order to be able to start clinical exploration of the dye.
In the present study, a technical protocol was designed to
produce covalently conjugated nanocolloidal albumin-IRDye
800CW in a cGMP-compliant way. Conjugation efficiency,
purity, stability, fluorescence quantum yield and particle size of
the nanocolloidal albumin-IRDye 800CW were determined.
Proof-of-principle studies with this conjugate were performed
inarabbitlymphogenicmetastatictumourmodel,whichmimics
HNSCC [18,19] .I nt h e s ei nv i v os t u d i e s ,I C Gm i x e dw i t hH S A
was evaluated as a reference, since this combination is often
used in clinical fluorescence imaging studies on SN detection.
Materials and methods
Materials
All reagents were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise stated. ICG (molecular weight
775 Da) was purchased from PULSION Medical Systems
(München, Germany), and diluted to a concentration of
2.5 μg/μl by adding 0.9% NaCl. IRDye 800CW N-hydrox-
ysuccinimide (NHS) ester (molecular weight 1,166 Da; LI-
COR Biosciences, Lincoln, NE) was supplied by Westburg
(Leusden, The Netherlands), and dissolved in DMSO to a
concentration of 0.58 μg/μl. Nanocoll was purchased from
GE Healthcare (Eindhoven, The Netherlands) as a kit for
labelling with
99mTc, containing amongst other components
0.5 mg lyophilized nanocolloidal albumin. The buffer used
for nanocolloidal albumin-IRDye 800CW production con-
sisted of 7.35 mg/ml sodium citrate with 0.7 mg/ml Tween-
80 diluted in deionized (18 MΩ·cm) water, and is referred to
1162 Eur J Nucl Med Mol Imaging (2012) 39:1161–1168here as Tween-citrate buffer (TCB). VX2 tumour cells were
kindly provided by Dr. RJ van Es (Department of Oral and
Maxillofacial Surgery, University Medical Center Utrecht,
Utrecht, The Netherlands). Female rabbits (HsdIf:NZW),
weighing1.5–2.5kg,werepurchasedfromHarlanLaboratories
(Hillcrest, Loughborough, UK).
Preparation of nanocolloidal albumin-IRDye 800CW
IRDye 800CW was coupled covalently to nanocolloidal albu-
minaccordingtothefollowingprocedure.TCB(1ml)adjusted
with 0.1 M Na2CO3 to pH 8.5, was added to a Nanocoll kit
vial, and 0.5 mg of nanocolloidal albumin was purified by
separating it from stannous chloride and other (small molecu-
lar) ingredients present in the kit (i.e. glucose, poloxamer 238,
sodiumphosphateandsodiumphytate)bysize-exclusionchro-
matography using a PD10 column (GE Healthcare Life Scien-
ces) with TCB (pH 8.5) as eluent. The void volume and the
first1.5mlwerediscarded;thenext2mlcontainedthepurified
nanocolloidalalbumin.Subsequently,to1mleluatecontaining
the purified nanocolloidal albumin (0.25 mg, corresponding to
3.7 nmol HSA building blocks, pH 8.5) was added 11.6 μgo f
IRDye 800CW-NHS ester (10 nmol in 20 μlD M S O ;a2 . 7
molar excess over HSA units that appeared to provide a
product with optimal fluorescence yield), and the mixture
was incubated for2 hat35°C.After2 h, nonconjugated IRDye
800CWwasremovedby size exclusionchromatographyusing
a PD10 column and TCB (pH 6.5) as eluent. The void volume
and the first 1.5 ml were discarded; the next 2 ml containing
the nanocolloidal albumin-IRDye 800CW conjugate was
used for further experiments.
Determination of conjugation efficiency
The efficiency of conjugation of IRDye 800CW to nano-
colloidal albumin was determined based on absorbance
measurements using an Ultrospec III spectrophotometer
(Pharmacia, Biotech, Roosendaal, The Netherlands) at a
wavelength of 774 nm. Since the absorption spectrum of
IRDye 800CW changes upon conjugation to nanocolloidal
albumin, calculations were based on the absorbance of free/
hydrolysed IRDye 800CW in the solution. There were no
differences in absorbance between the IRDye 800CW-NHS
ester and the hydrolysed IRDye 800CW (Fig. 1). Due to
their colloidal nature, direct HPLC analysis of nanocolloidal
albumin particles was considered not to be an option.
Absorbance measurements were performed directly after
addition of IRDye 800CW-NHS ester to the nanocolloidal
albumin solution (Absstart) and after 2 h conjugation time. At
the latter time, both nanocolloidal albumin-IRDye 800CWas
well as free (hydrolysed) IRDye 800CW are present in the
reaction mixture. In order to differentiate between conjugated
nanocolloidal albumin-IRDye 800CW and free IRDye
800CW, a twofold volume excess of acetonitrile (MeCN)
was added to the reaction mixture for precipitation of the
nanocolloidal albumin. Subsequently, the absorbance of the
supernatant(Abssup) was measured,whichhadtobemultiplied
by 3 for correction of the dilution by MeCN. Conjugation
efficiency was calculated using the expression:
conjugation efficiency ¼ 1:0  
3   Abssup
Absstart

  100%
To prove that binding of IRDye 800CW to nanocolloidal
albumin is based on covalent bonds and not on association,
control measurements were carried out using hydrolysed
IRDye 800CW. To this end, 20 nmol IRDye 800CW-NHS
ester in 40 μl DMSO was added to 2 ml TCB (pH 8.5) and
incubated for 2 h at 35°C, which resulted in >95% hydrolysis
of the NHS ester (supplementary Fig. S1). Subsequently, the
hydrolysed IRDye 800CW was added to a kit vial containing
0.5 mg nanocolloidal albumin and the mixture was incubated
for an additional 2 h at 35°C. After measurement of absor-
bance, the nanocolloidal albumin was precipitated and the
absorbance of the supernatant determined as described above.
In addition, this method was also applied to determine the
purity of thefinal nanocolloidal albumin-IRDye800CW prod-
uct andits stability as a function of time (measured over 120 h).
For further verification of the validity of the precipitation
method, a reaction was performed using similar amounts of
protein and IRDye 800CWas described above, but with native
HSA instead of nanocolloidal albumin. With this approach
HPLC analysis is also possible. After the 2-h reaction period,
HPLCoftheconjugationmixturewasperformedusingaJasco
HPLC system equipped with a Superdex 200 10/30 GL size-
exclusion column (GE Healthcare Life Sciences) with a mix-
ture of 0.05 M sodium phosphate (pH 6.8), 0.15 M sodium
chloride and 0.01 M NaN3 as the eluent at a flow rate of
0.5ml/min. Theareaunderthe curve inthe 780nmchannelof
the hydrolysed IRDye 800CW peak at Rt050.4 min upon
Fig. 1 Absorbance spectrum of IRDye 800CW-NHS ester, hydrolysed
IRDye800CW, and nanocolloidal albumin-IRDye 800CW
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pared with the area under the curve of hydrolysed IRDye
800CW incubated in the absence of HSA. The precipitation
method as described above was then applied.
Particle size measurements of nanocolloidal albumin-IRDye
800CW
For determination of the particle size, nanocolloidal
albumin-IRDye 800CW was analysed by atomic force mi-
croscopy (AFM), which is a single-particle technique that
has been used successfully to characterize a wide variety of
nanometre-sized proteinaceous assemblies [20–22]. The
atomic force microscope (Nanotec Electronica, Tres Cantos,
Spain) was operated in jumping mode and all experiments
were performed in liquid. Rectangular cantilevers (Olympus
RC800PSA) with a nominal tip radius of 20 nm and spring
constant of 0.05 N/m were used to image the colloidal
particles. Colloidal samples were deposited on freshly
cleaved mica substrate, and incubated for 10 min before
analysis by AFM. As a reference, the native contents of a
Nanocoll kit, diluted in TCB pH 6.5) to a concentration of
0.10 mg/ml nanocolloidal albumin were analysed. The
height of immobilized particles was determined automati-
cally using an in-house program written in LabView (Na-
tional Instruments) to obtain the particle size distribution.
Fluorescence properties
The fluorescence properties of nanocolloidal albumin-IRDye
800CW were determined using a FluoroMax-3 spectrofluo-
rometer (Horiba Jobin Yvon, Edison, NY) and absorbance
(corrected for background measurements) was measured us-
ing an UltroSpec 1100 Pro spectrophotometer (Amersham
Pharmacia). Absorbance was always <0.1, in order to avoid
confounding effects such as self-quenching and self-
absorption. Measurements were performed in human serum,
which was diluted fourfold with TCB (pH 6.5) in order to
mimictheinvivoproteinconcentrationofthelymphaticfluid,
part of the interstitial body fluid, as well as in TCB (pH 6.5)
alone. Comparative measurements were done for ICG. All
measurements were carried out using freshly prepared IRDye
800CW-NHS ester (before conjugation) and ICG in order to
minimize the possibility of degradation effects of ICG and
IRDye 800CW. In addition, all spectrofluorometer measure-
ments were performed immediately after determination of
absorbance. The excitation wavelength was 785 nm, and
emissionwasmeasuredovertherange790–1,000nm.Spectra
were corrected for the emission spectrum of a blank serum or
TCBsampleandforthe intensity fluctuationsofthe excitation
source. For the samples in TCB, the absolute quantum yield
was determined using ICG in ethanol (quantum yield of
13.2%) as the fluorescence standard [23]. For the samples in
serum, the absolute quantum yields could not be determined
due to the turbidity of the solutions. Therefore, for these
samples relative quantum yields were reported comparing
nanocolloidal albumin-IRDye 800CW to ICG.
Preparation of injectable ICG/HSA solution
The noncovalent ICG/HSA injectate was mixed as de-
scribed by Ohnishi et al. [16]. To 33.5 mg HSA dissolved
in 50 ml phosphate-buffered saline (pH 7.4) was added
0.16 ml of a 2.5-mg/ml ICG solution to achieve a final
concentration of 10 μM each (1:1 molar ratio). After gentle
mixing the ICG/HSA solution was ready for in vivo use.
In vivo experiments
For in vivo evaluation, New Zealand white rabbits bearing
auricular VX2 carcinomas were used. This animal model
(Fig. 2a) is attractive for evaluating SN detection procedures
in HNSCC, since after inoculation of tumour cells into the
external ear the developing tumours tend to metastasize
lymphatically. The first lymph node that is metastatically
involved in this model is the parotid lymph node, the “SN”;
caudal mandibular lymph nodes are considered to be higher
tier lymph nodes in this model. The consistent lymphogenic
metastatic spread of the tumour and the accessibility of the
lymph nodes for surgery make this a very suitable model for
evaluation of SN detection [18, 19]
Auricular VX2 carcinoma cell suspensions (0.15–0.25 ml
containing 25–30×10
6 VX2 tumour cells), obtained after in-
tramuscular passaging of tumours via the hind limb in other
rabbits, were injected into both ears essentially as described by
Dünne et al. [19]. Experiments were performed 1–2w e e k s
after injection of the VX2 tumour cell suspension. Before
injection of the tumour cell suspension and of the fluorescent
tracer as well as during imaging procedures, animals were
anaesthetized with a combination of dexmedetomidine
(0.5 mg/kg,Dexdomitor) and ketamine (100 mg/ml, Ketamine
10%). Animals were killed with an overdose of pentobarbital
(200 mg/ml, Euthasol 20%) administered intravenously under
anaesthesia. All animal experiments were performed in
accordance with Dutch animal welfare regulations and Dutch
national law (Wet op de dierproeven, Stb 1985, 336).
The fluorescent tracers nanocolloidal albumin-IRDye
800CW (six tumours) and ICG/HSA (six tumours) were al-
ways administered via four peritumoral subcutaneous injec-
tions of 0.25–0.5 ml each and the total injected volume was at
least 1 ml. Early NIR fluorescence imaging was performed
during injectionandwascontinued until30 min after injection;
late NIR fluorescence image registration was performed after
24 h, with the same imaging settings and positioning of the
animal, to allow evaluation of long-term retention of the tracer
in the draining lymph nodes. After the late imaging
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guided resection of fluorescent lymph nodes was performed.
NIR fluorescence imaging
NIR fluorescence imaging was performed using a Fluobeam
NIR imaging system (Fluoptics, Grenoble, France), which is
suitable for preclinical as well as clinical applications. This
system is compact and portable. It consists of two parts: a
control unit with a laser source emitting at 785 nm and a
power supply for light-emitting diodes (LEDs), next to an
optical head with a highly sensitive charge-coupled device
camera and white LEDs for field illumination. The laser
beam is fibre-guided from the control unit to the optical
head. The laser beam was spread to reach a 6-cm spot
diameter at the working distance of 17 cm. The power
density of the laser irradiation was 96 μW/mm
2. The NIR
fluorescence image was 696×512 pixels and provided a
resolution of two line pairs per millimetre allowing visual-
ization of submillimetre structures. The imaging settings of
the Fluobeam were adjusted to obtain the best view on the
monitor and the best fluorescence-to-background ratio.
Results
Preparation and characterization of nanocolloidal
albumin-IRDye 800CW
Coupling of IRDye 800CW to nanocolloidal albumin as
well as native HSA resulted in a conjugation yield of about
50% as determined by a fluorescence spectrophotometer
(precipitation method) and/or HPLC. As a result, on average
1.4 IRDye 800CW molecules were coupled per HSA mol-
ecule (about 67 kDa) in the nanocolloidal albumin particles.
Buckle et al. [24] estimated the molecular weight of a nano-
colloidal albumin particle to be about 670 kDa, and this
means that a nanocolloidal albumin particle contained on
average 14 covalently bound dye molecules. The presence
of Tween-80 in the reaction mixture as well as in the PD10
column eluent minimized the amount of associated non-
covalently bound dye in the end product, as was shown by
control reactions with hydrolysed IRDye 800CW and nano-
colloidal albumin (<3%). In general, nanocolloidal albumin-
IRDye 800CW appeared to contain<2% of free IRDye
800CW after purification, and this percentage did not
change during 120 h of storage. The particle size distribu-
tions are shown in Fig. 3. The average size of the nano-
colloidal albumin-IRDye 800CW was similar to the average
size of native nanocolloidal albumin: 14.6±0.4 nm and
14.1±1.5 nm, respectively. In serum, the relative quantum
yieldsofnanocolloidalalbumin-IRDye800CWandICGwere
0.96 and 1.0, respectively. Absolute quantum yields of nano-
colloidal albumin-IRDye 800CWand ICG in TCB were 8.0±
0.2% and 8.6±0.1%, respectively.
In vivo experiments
In all experiments draining lymph nodes (parotid lymph
node and caudal mandibular lymph node) became visible
within 5 min by noninvasive imaging of either nanocolloidal
albumin-IRDye 800CW (Fig. 2b) or ICG/HSA (Fig. 2d).
Fig. 2 In vivo evaluation of
nanocolloidal albumin-IRDye
800CW. a Rabbit VX2 auricu-
lar carcinoma model. The red
box represents the field of view
of images b–e. b, c NIR
fluorescence image of
fluorescence-labelled lymph
nodes obtained 5 min (b) and
24 h (c) after peritumoral
injection of nanocolloidal
albumin-IRDye 800CW
(exposure time 500 ms). d, e
NIR fluorescence image of
fluorescence-labelled lymph
nodes obtained 5 min (d) and
24 h (e) after peritumoral
injection of ICG/HSA
(exposure time 1000 ms)
(1 parotid lymph node, 2 caudal
mandibular lymph nodes,
a angle of mandible, T tumour)
Eur J Nucl Med Mol Imaging (2012) 39:1161–1168 1165After 24 h, noninvasive NIR fluorescence imaging was still
able to identify the same 12 draining lymph nodes (parotid
and caudal mandibular lymph nodes) in six of six tumours
(100%) injected with nanocolloidal albumin-IRDye 800CW,
without a decrease in signal intensity and without an in-
crease in background fluorescence (Fig. 2c). However, after
24 h, SNs identified with ICG/HSA during early imaging
showed an observable decrease in fluorescence signal, while
in 4 of 12 lymph nodes (33%) the fluorescence signal was
completely absent (Fig. 2e). Even after open surgery with
adjustment of the Fluobeam camera settings (e.g. highest
exposure time), these lymph nodes were not detectable.
Once a fluorescence signal was detected, it was easy to
excise the SN because of the clear delineation of the
fluorescence-labelled lymph nodes and the high target-to-
background ratio (Fig. 4).
Discussion
We describe here the covalent conjugation of the fluorescent
dye IRDye 800CW to nanocolloidal albumin. The method is
very simple and reproducible, and leads to about 14 IRDye
800CW groups per nanocolloidal albumin particle, yielding
a strong fluorescence signal intensity. In addition, the size of
the nanocolloidal albumin particles was not altered after
conjugation to IRDye 800CW, and was shown to be com-
parable with that of the gold standard
99mTc-Nanocoll [25].
In vivo experiments in a lymphogenic metastatic animal
model showed noninvasive NIR fluorescence detection of
the SN up to 24 h after injection of the tracer, without any
loss of fluorescence intensity, while comparative experi-
ments with ICG/HSA showed a strong decrease or complete
loss of fluorescence intensity by 24 h after injection. These
characteristics of imaging with nanocolloidal albumin-
IRDye 800CW offer an attractive alternative to current pro-
cedures for SN detection. The feasibility of NIR
fluorescence-guided SN detection has been demonstrated
in a variety of tumour types where ICG was used as the
fluorescent tracer [6–13, 26, 27]. To date, however, there are
just a few small studies which aimed to compare ICG-based
SN detection with the standard of care
99mTc-Nanocoll and
Fig. 3 Size distribution of nanocolloidal albumin-IRDye 800CW and
native nanocolloidal albumin as assessed by AFM imaging. AFM
measured the height of a particle, which represents particle size
Fig. 4 Noninvasive real-time
NIR fluorescence detection of a
fluorescence-labelled lymph
node in the neck of a rabbit. a
Preoperative image after
administration of nanocolloidal
albumin-IRDye800CW
(a angle of mandible, arrow
lymph node, N neck). b
Intraoperative image after
preparation of a skin flap
(a angle of mandible). c, d
Removal of the lymph node (c)
after which no fluorescence
signal is detectable (d)
indicating complete removal of
fluorescence-containing
tissues. Note the high contrast
between the fluorescent lymph
node and the surrounding
tissue. Exposure time in all
images was 200 ms
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to address whether NIR fluorescence imaging alone can
replace radiocolloids and/or blue dyes are ongoing [9].
A critical aspect in the use of NIR fluorescence imaging is
its limited tissue penetration, which might hamper SN detec-
tion in the neck when a thick layer (>1 cm) of overlaying
tissue is present as might be found in obese patients. This
aspect is very important when considering the use of fluores-
cence imaging as the sole technique for SN detection. A
particular drawback of the use of ICG is its small particle size,
which reduces its retention time in the SN and results in rapid
spread to higher tier nodes. If a tracer migrates to higher tier
nodes, the practical inconvenience arises that nonsentinel
lymph nodes are incorrectly identified as SN, leading to the
riskofmissingametastatic(real)SNandtheresectionofmore
nodes than necessary. This is particularly challenging in the
complex anatomy of the neck. In preclinical studies it was
demonstrated that ICG adsorption to HSA improves its per-
formance as a lymphatic tracer. However, a clinical random-
ized, double-blind trial comparing ICG with or without
albumin premixing for SN detection in breast cancer patients
did not reveal any benefit of ICG premixed with HSA [28].
Buckle et al. developed a so-called self-assembled mul-
timodal complex, which consists of ICG noncovalently as-
sociated with
99mTc-Nanocoll. Similar migration properties
of ICG and
99mTc-Nanocoll were observed immediately
after injection [24]. However, most probably because of
the noncovalent interaction of ICG and
99mTc-Nanocoll,
dissociation of ICG from
99mTc-Nanocoll was observed,
resulting in fluorescent lymph nodes that did not contain
radioactivity and therefore could not be considered SNs
[29]. Although the clinical feasibility of SN detection with
this multimodal complex has been demonstrated [30], the
approach as a whole still suffers from the same intrinsic
limitations related to ICG as described above.
Our developed technical protocol for labelling and purifi-
cation ensures that >98% of the IRDye 800CW is covalently
bound to the nanocolloidal albumin. In this study, in order to
mimic the clinically most relevant situation, we determined the
quantum yield of nanocolloidal albumin-IRDye 800CW rela-
tive to that of ICG in human serum with a composition resem-
bling lymphatic fluid, i.e. serum diluted with TCB, and
demonstrated that the quantum yields of nanocolloidal
albumin-IRDye 800CW and ICG are very similar. The abso-
lute quantum yields of nanocolloidal albumin-IRDye 800CW
andICGinTCBwerealsosimilar(8.0%vs.8.6%,respectively).
Therefore, our results do not support the reported limitation in
the utility of nanocolloidal albumin-IRDye 800CW as a con-
sequence of intra- and intermolecular quenching [16].
Our in vivo experiments exhibited strong fluorescence sig-
nals (Fig.4).Moreover,nanocolloidalalbumin-IRDye800CW
showed superior SN retention in our lymphogenic metastatic
animal model, and demonstrated comparable particle size and
similar kinetics to those we recently described for the SPECT
tracer
99mTc-Nanocoll and the novel PET tracer
89Zr-nano-
colloidal albumin in the same animal model [25]. With the
new IRDye 800CW tracer, parotid and caudal mandibular
lymph nodes became visible within 5 min of injection,
remained clearly visible until at least 24 h after injection
without an increase in local background activity, and the
information provided with this conjugate was fully congruent
with that obtained using the PET tracer
89Zr-nanocolloidal
albumin at 24 h (see supplementary Fig. S2). This makes
possible the direct clinical comparison of the detection of SN
using nanocolloidal albumin-IRDye 800CW with the standard
of care
99mTc-Nanocoll and patent blue in a 2-day procedure.
In such a first-in-human clinical trial, nanocolloidal albumin-
IRDye 800CW can simply be coinjected with
99mTc-Nanocoll
24 h before SN removal, since the logistic advantage of nano-
colloidal albumin-IRDye 800CW is its potential as an off-the-
shelf product. The first clinical objective is the assessment of
the SN detection rate and sensitivity of fluorescence imaging,
becausethedoseofnanocolloidalalbum-IRDye800CWmight
be critical as was previously observed for ICG. Nevertheless,
we think that the excellent SN fluorescence imaging results
obtained in the lymphogenic metastatic animal model can be
translated to the human situation in which the same amount of
injected volume (1–2 ml) can be used. Although lymph nodes
in the head and neck region are often located superficially, the
major challenge is expected to be the detection of deep-seated
SNs. These trials will determine whether fluorescence detec-
tion with nanocolloidal albumin-IRDye 800CW can either
replace just the intraoperative blue dye or the gamma probe
procedure. Ideally, it has to be shown whether it can also
replacepreoperativescintigraphicimagingcompletelyresulting
in a one-step procedure of NIR fluorescence imaging that takes
place entirely during surgery.
Conclusion
Nanocolloidal albumin-IRDye 800CW is a promising next-
generation fluorescent tracer with characteristics that would
allow intraoperative SN detection even after a longer inter-
val of time. This makes a reliable comparison between the
use of fluorescence-guided detection and the conventional
radioactive-guided method possible.
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